Because biomarkers are typically low in abundance, the crucial step of biomarker discovery is to efficiently separate clinically relevant sets of proteins that might define disease stages and/or predict disease development. It is anticipated that a multi-dimensional fractionation system (MDFS) will provide an efficient means of separating low abundance proteins from plasma proteins, resulting in the extension of the detection limit. However, when using an MDFS to analyze the plasma proteome it is important to consider how sample processing, yield, resolution and throughput potential may influence the detection limit. This review evaluates the recent advances in MDFS research with respect to '4RS criterion' (4R: resolution, reproducibility, recovery, and robustness; 4S: simplicity, speed, selectivity and sensitivity) and discusses perspectives for future plasma-derived biomarker discovery.
Bibliographical noteFunding Information:
This work is supported by grants from the Research Grants Council of Hong Kong (N_CUHK413/12 to H Z and 463013 to CHKC), the National Natural Science Foundation of China (31172394 to CHKC) and the Shenzhen Municipal R&D Fund of Science and Technology (GJHS20120702105523308 to CHKC). We thank colleagues in our laboratories for helpful discussion on this project.
All Science Journal Classification (ASJC) codes
- Analytical Chemistry